Dr Kathryn Therese Mngadi

Dr Kathryn Therese Mngadi

Person

Dr Kathryn Therese Mngadi

Telephone

Email

Kathy.Mngadi@caprisa.org

Campus

Medical School

Research Interests

HIV Vaccines

Designation

Honorary Lecturer

Biosketch
Dr Kathryn Mngadi (MBChB, Dip HIV Man SA, MPhil Pall Med, Dip Epi, Dip Clin Trials) is a South African investigator who has worked mainly in HIV and TB prevention trials for the last 12 years. She qualified at the Nelson Mandela School of Medicine at the University of Kwazulu Natal in 1988, and worked in clinical medicine initially with a focus on HIV palliation, before ART was available, and in TB treatment. She joined Anglogold Health Services in the first programme in South Africa to offer ART for HIV, and worked with The Aurum Institute on HIV treatment protocols. She joined Aurum in 2004 where she worked in prevention research including HIV vaccines, acute HIV infection and TB vaccine and treatment trials, collaborating with HVTN, IAVI, CHAVI, MTN, Aeras, Johnson and Johnson and the Bill and Melinda Gates Foundation. She joined CAPRISA in 2011 as the Project Director for CAPRISA 008 a microbicide trial combining post-trial access with implementation science; currently she is the Principal Investigator for all HIV Vaccine Trial Network vaccine trials and the protocol co-chair and national Principal Investigator for HVTN 107, a preventive HIV Vaccine trial comparing MF59 and alum adjuvants, with a DNA prime and combined DNA+protein boost. She sits on the Scientific Governance Committee, the Efficacy Working Group, the Protocol Review Committee and on the Investigator Working Groups for the HIV Vaccine Trials Network, and is an honorary lecturer at the University of Kwazulu-Natal since November 2014, in the School of Laboratory Medicine and Medical Science. She has recently accepted an invitation to the CAPRISA Scientific Review Committee.

 

List of Publications 
Peer Reviewed Publications
1. Hanifa Y, Mngadi K, Lewis J, Fielding K, Churchyard G, Grant AD. Evaluation of the Arkansas method of urine testing for isoniazid in South Africa. Int J Tuberc Lung Dis. 2007; 11(11):1232-1236.
2. Grant AD, Coetzee L, Fielding KL, Lewis JJ, Ntshele S, Luttig MM, et al. ‘Team up against TB’: promoting involvement in Thibela TB, a trial of community-wide tuberculosis preventive therapy. Aids. 2010; 24 Suppl 5:S37-44.
3. Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ. Adverse events with isoniazid preventive therapy: experience from a large trial. Aids. 2010; 24 Suppl 5:S29-36.
4. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis. 2014.
5. Mngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, et al. Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 Trial. AIDS and Behavior. 2014.
6. Mansoor LE, Abdool Karim Q, Mngadi KT, Dlamini S, Montague C, et al. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. Trials. 2014.
7.           Mngadi KT, Dlamini S, Mvandaba M, Nkomonde N, Frolich JA, Singh J, Abdool Karim Q and Mansoor LE. Challenges with Participant Reimbursement: Experiences from a Post-trial Access Study. JME. 
8. Moodie Z et al. Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. PlosOne 2015.
9. Baden et al. An International Study to Assess the Safety and Immunogenicity of Heterologous and Homologous Ad26.EnvA and Ad35-Env HIV-1 Vaccine Regimens in Healthy HIV Negative Adults. Annals of Internal Medicine 2016.

Other (Conference Presentations, Posters etc.)

1. Churchyard G, Mngadi K. A Protecting Your Workforce from Tuberculosis: A Toolkit for an Integrated Approach to TB and HIV for Businesses in South Africa. World Economic Forum, May 2008

2. Mngadi K, Cameron D. Integration of Palliative Care with Antiretroviral Therapy and other AIDS-Specific Treatments , A Clinical Guide to Supportive and Palliative Care for HIV/AIDS in Sub-Saharan Africa, Chapter 11.10, 2005.
3. Cameron D, Mngadi K. Principles of Clinical Assessment (secondary author – lead author Dave Cameron), A Clinical Guide to Supportive and Palliative Care for HIV/AIDS in Sub-Saharan Africa, Chapter 11.1, 2005.
4. Operational challenges implementing a community intervention in an industrial setting, 38th IUATLD Conference, 2007.
5. Eligibility criteria for Isoniazid Preventive Therapy in a community-wide isoniazid prevention therapy study, 38th IUATLD Conference, 2007.
6. Adverse event experience in workplace setting of wide-spread isoniazid preventive therapy, 38th IUATLD Conference, 2007. [Poster]
7. Does disclosure of microbicide gel use to sexual partner influence adherence? 6th SAAIDS Conference, June 2013, Mngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, et al [Oral presentation]
8. Increasing Cervical Cancer Screening in a Family Planning Clinic using a Quality Improvement Approach, Mvandaba N, Mansoor LE, Tshabalala M, Mngadi K, Abdool Karim SS and Abdool Karim Q, HASA 2013 Conference: Quality Improvement Summit, Cape Town, 28 to 30 Oct 2013. [Poster]
9. Participant Deception: A Case Study in CAPRISA 008. Kathryn T. Mngadi, Nomzamo Mvandaba, Nonhlanhla Langa, Ntombifuthi Mkhize, Charlene Harichund, Quarraisha Abdool Karim and Leila E Mansoor. HIV Research for Prevention Conference, October 2014, Cape Town. [Poster]
10. Challenges with Participant Reimbursement: Experiences from a Post-trial Access Study. Kathryn T. Mngadi, Janet Frohlich, Carl Montague, Jerome Singh, et al. HIV Research for Prevention Conference, October 2014, Cape Town. [Oral presentation]